- Diflomotecan, a promising homocamptothecin for cancer therapy
[作者:Kroep, JR; Gelderblom, H,期刊:Expert opinion on investigational drugs, 页码:69-75 , 文章类型: Article,,卷期:2009年18-1]
Diflomotecan, a 10,11-difluoro-homocamptothecin, represents a new promising class of topoisomerase I inhibitors with enhanced plasma stability and superior preclinical anti-tumour activity as compared to the establish...
- Milatuzumab: a promising new agent for the treatment of lymphoid malignancies
[作者:Mark, T; Martin, P; Leonard, JP; Niesvizky, R,期刊:Expert opinion on investigational drugs, 页码:99-104 , 文章类型: Article,,卷期:2009年18-1]
Background: Non-Hodgkin's lymphoma and multiple myeloma are often incurable and respond to a limited set of treatment options. The selective expression of CD74, the invariant chain of the MHC class II molecule, in the...
- New directions in pharmacological treatment of acromegaly
[作者:Bollerslev, J; Fougner, SL; Berg, JP,期刊:Expert opinion on investigational drugs, 页码:13-22 , 文章类型: Review,,卷期:2009年18-1]
Background/objectives: The aim of treatment for acromegaly is to control tumour growth, relieve symptoms and ensure biochemical cure. With specific, well-tolerated medication, long-time primary or preoperative treatme...
|